No currently available pharmacologic approaches cure patients, since JAK1/2 inhibitors Ruxolitinib and Fedratinib are effective in reducing splenomegaly and inflammation-related symptoms but do not affect BM fibrosis and disease burden in most cases [10] and rIFN-α has proven to improve BM morphology only in a fraction of PMF patients [13, 14]. This evidence concerns the gene JAK1 and Splenomegaly.